000			03104nam a2200277 4500
001			ESSALUD
005			20260805001645.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aRuella, Marco _eAutor _953883
245			_aTen-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
300			_apáginas: 2440-2448
520			_aBackground: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. Methods: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) — autologous T cells expressing CD19-directed, 4-1BB–costimulated chimeric receptors. Lymphoma-free survival was defined as the time from the tisagenlecleucel infusion to relapse or lymphoma-related death. The incidence of non–relapse-related death and second primary cancer was estimated with the Aalen–Johansen method. The data-cutoff date was October 1, 2025. Results: At a median follow-up of 10.1 years (range, 7.9 to 11.5), no relapses had occurred beyond 5.4 years. The 10-year lymphoma-free survival was 32% (95% confidence interval [CI], 14 to 51) among patients with large B-cell lymphoma and 47% (95% CI, 20 to 71) among those with follicular lymphoma. In an analysis that included deaths from any cause, the 10-year progression-free survival was 17% (95% CI, 5 to 34) among patients with large B-cell lymphoma and 29% (95% CI, 9 to 52) among those with follicular lymphoma; the 10-year overall survival was 17% (95% CI, 5 to 34) and 50% (95% CI, 23 to 72), respectively. Persistent grade 2 or 3 neutropenia occurred in 2 patients (5%); no late anemia or thrombocytopenia was observed. A second primary cancer developed in 9 patients (10-year cumulative incidence, 21%). The 10-year non–relapse-related mortality was 18% (14% when deaths related to coronavirus disease 2019 were excluded). Higher CAR-transgene persistence appeared to be associated with long-term response. B-cell aplasia persisted in 44% of patients with a long-term response. Conclusions: Among patients with heavily pretreated B-cell non-Hodgkin lymphoma, a single infusion of tisagenlecleucel led to decade-long remissions (lymphoma-free survival) in approximately one third of the patients with large B-cell lymphomas and in nearly one half of those with follicular lymphoma.
650			_aLEUCEMIA _933873
650			_aLINFOMA _939360
650			_aTRATAMIENTOS EN ONCOLOGÍA _953734
700			_aParuzzo, Luca _953884
700			_aChong, Emeline R. _953885
700			_aChong, Elise A. _953886
700			_aLandsburg, Daniel J. _953887
700			_aNasta, Sunita D. _953888
773	0		_022717 _922639 _dMassachusetts NEJM Group _oNEJM006 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-07-31 _zSQB
999			_c22763 _d22763